Literature DB >> 33288640

In Vitro Characterization of the Carbohydrate-Binding Agents HHA, GNA, and UDA as Inhibitors of Influenza A and B Virus Replication.

Evelien Vanderlinden1, Nathalie Van Winkel2, Lieve Naesens2, Els J M Van Damme3, Leentje Persoons2, Dominique Schols2.   

Abstract

Here, we report on the anti-influenza virus activity of the mannose-binding agents Hippeastrum hybrid agglutinin (HHA) and Galanthus nivalis agglutinin (GNA) and the (N-acetylglucosamine) n -specific Urtica dioica agglutinin (UDA). These carbohydrate-binding agents (CBA) strongly inhibited various influenza A(H1N1), A(H3N2), and B viruses in vitro, with 50% effective concentration values ranging from 0.016 to 83 nM, generating selectivity indexes up to 125,000. Somewhat less activity was observed against A/Puerto Rico/8/34 and an A(H1N1)pdm09 strain. In time-of-addition experiments, these CBA lost their inhibitory activity when added 30 min postinfection (p.i.). Interference with virus entry processes was also evident from strong inhibition of virus-induced hemolysis at low pH. However, a direct effect on acid-induced refolding of the viral hemagglutinin (HA) was excluded by the tryptic digestion assay. Instead, HHA treatment of HA-expressing cells led to a significant reduction of plasma membrane mobility. Crosslinking of membrane glycoproteins, through interaction with HA, could also explain the inhibitory effect on the release of newly formed virions when HHA was added at 6 h p.i. These CBA presumably interact with one or more N-glycans on the globular head of HA, since their absence led to reduced activity against mutant influenza B viruses and HHA-resistant A(H1N1) viruses. The latter condition emerged only after 33 cell culture passages in the continuous presence of HHA, and the A(H3N2) virus retained full sensitivity even after 50 passages. Thus, these CBA qualify as potent inhibitors of influenza A and B viruses in vitro with a pleiotropic mechanism of action and a high barrier for viral resistance.
Copyright © 2021 American Society for Microbiology.

Entities:  

Keywords:  CBA; antiviral; fusion; glycans; hemagglutinin; influenza

Mesh:

Substances:

Year:  2021        PMID: 33288640      PMCID: PMC8092504          DOI: 10.1128/AAC.01732-20

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  85 in total

1.  Carbohydrate binding properties of the stinging nettle (Urtica dioica) rhizome lectin.

Authors:  N Shibuya; I J Goldstein; J A Shafer; W J Peumans; W F Broekaert
Journal:  Arch Biochem Biophys       Date:  1986-08-15       Impact factor: 4.013

Review 2.  Baloxavir marboxil: the new influenza drug on the market.

Authors:  Ryan O'Hanlon; Megan L Shaw
Journal:  Curr Opin Virol       Date:  2019-03-08       Impact factor: 7.090

3.  Aniline-Based Inhibitors of Influenza H1N1 Virus Acting on Hemagglutinin-Mediated Fusion.

Authors:  Rosana Leiva; Marta Barniol-Xicota; Sandra Codony; Tiziana Ginex; Evelien Vanderlinden; Marta Montes; Michael Caffrey; F Javier Luque; Lieve Naesens; Santiago Vázquez
Journal:  J Med Chem       Date:  2017-12-22       Impact factor: 7.446

Review 4.  Current and future influenza vaccines.

Authors:  Seiya Yamayoshi; Yoshihiro Kawaoka
Journal:  Nat Med       Date:  2019-01-28       Impact factor: 53.440

5.  N-linked glycosylation facilitates sialic acid-independent attachment and entry of influenza A viruses into cells expressing DC-SIGN or L-SIGN.

Authors:  Sarah L Londrigan; Stuart G Turville; Michelle D Tate; Yi-Mo Deng; Andrew G Brooks; Patrick C Reading
Journal:  J Virol       Date:  2010-12-29       Impact factor: 5.103

6.  Effect of hemagglutinin glycosylation on influenza virus susceptibility to neuraminidase inhibitors.

Authors:  Vasiliy P Mishin; Dmitri Novikov; Frederick G Hayden; Larisa V Gubareva
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

Review 7.  Carbohydrate-binding agents: a potential future cornerstone for the chemotherapy of enveloped viruses?

Authors:  Jan Balzarini
Journal:  Antivir Chem Chemother       Date:  2007

8.  Crystal structure of unliganded influenza B virus hemagglutinin.

Authors:  Qinghua Wang; Feng Cheng; Mingyang Lu; Xia Tian; Jianpeng Ma
Journal:  J Virol       Date:  2008-01-09       Impact factor: 5.103

9.  A molecularly engineered antiviral banana lectin inhibits fusion and is efficacious against influenza virus infection in vivo.

Authors:  Evelyn M Covés-Datson; Steven R King; Maureen Legendre; Auroni Gupta; Susana M Chan; Emily Gitlin; Vikram V Kulkarni; Jezreel Pantaleón García; Donald F Smee; Elke Lipka; Scott E Evans; E Bart Tarbet; Akira Ono; David M Markovitz
Journal:  Proc Natl Acad Sci U S A       Date:  2020-01-13       Impact factor: 11.205

10.  The influenza virus hemagglutinin head evolves faster than the stalk domain.

Authors:  Ericka Kirkpatrick; Xueting Qiu; Patrick C Wilson; Justin Bahl; Florian Krammer
Journal:  Sci Rep       Date:  2018-07-11       Impact factor: 4.379

View more
  4 in total

1.  Anthranilamides with quinoline and β-carboline scaffolds: design, synthesis, and biological activity.

Authors:  Maja Beus; Leentje Persoons; Dirk Daelemans; Dominique Schols; Kirsi Savijoki; Pekka Varmanen; Jari Yli-Kauhaluoma; Kristina Pavić; Branka Zorc
Journal:  Mol Divers       Date:  2022-01-08       Impact factor: 3.364

2.  35 years in plant lectin research: a journey from basic science to applications in agriculture and medicine.

Authors:  Els J M Van Damme
Journal:  Glycoconj J       Date:  2021-08-24       Impact factor: 3.009

Review 3.  Legume Lectins with Different Specificities as Potential Glycan Probes for Pathogenic Enveloped Viruses.

Authors:  Annick Barre; Els J M Van Damme; Bernard Klonjkowski; Mathias Simplicien; Jan Sudor; Hervé Benoist; Pierre Rougé
Journal:  Cells       Date:  2022-01-20       Impact factor: 6.600

4.  Carbohydrate-binding protein from stinging nettle as fusion inhibitor for SARS-CoV-2 variants of concern.

Authors:  Emiel Vanhulle; Thomas D'huys; Becky Provinciael; Joren Stroobants; Anita Camps; Sam Noppen; Dominique Schols; Els J M Van Damme; Piet Maes; Annelies Stevaert; Kurt Vermeire
Journal:  Front Cell Infect Microbiol       Date:  2022-08-30       Impact factor: 6.073

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.